伊布替尼治疗复发或难治性T细胞淋巴瘤的初步试验
这项初步临床试验评估伊布替尼560和840 mg每日口服两个剂量水平,纳入14例复发或难治性外周T细胞淋巴瘤和皮肤T细胞淋巴瘤患者。两剂量均安全耐受,未观察到剂量限制性毒性;1例达部分缓解(总缓解率8%[1/13])。ITK占据率平均50%(范围15%-80%),高于50%的ITK占据率与更高的血清肿瘤坏死因子-α和干扰素-γ水平相关并倾向于Th1表型;数据提示伊布替尼抑制ITK在T细胞淋巴瘤中临床活性有限。
要点
- 伊布替尼560和840 mg每日口服两剂量均安全耐受,未观察到剂量限制性毒性。
- 14例患者中1例达部分缓解,总缓解率8%(1/13)。
- ITK占据率平均50%(范围15%-80%),高于50%与更高肿瘤坏死因子-α和干扰素-γ水平及Th1表型倾向相关。
核心结论
- 数据提示伊布替尼抑制ITK在T细胞淋巴瘤中临床活性有限。
研究设计与样本
- 初步临床试验评估伊布替尼560和840 mg每日口服两个剂量水平,纳入14例复发或难治性外周T细胞淋巴瘤和皮肤T细胞淋巴瘤患者。
- 研究注册于www.clinicaltrials.gov,编号NCT02309580。
主要发现
- 两剂量水平均安全耐受,未观察到剂量限制性毒性。
- 1例患者达部分缓解,总缓解率8%(1/13)。
- ITK占据率研究显示平均占据率50%(范围15%-80%)。
- 高于50%的ITK占据率与更高的血清肿瘤坏死因子-α和干扰素-γ水平相关,并倾向于Th1表型。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Ibrutinib has previously been shown to inhibit Bruton's tyrosine kinase (BTK) and interleukin-2-inducible T-cell kinase (ITK), which mediate B-cell and T-cell receptor signaling, respectively. BTK inhibition with ibrutinib has demonstrated impressive clinical responses in a variety of B-cell malignancies. Whether ibrutinib inhibition of ITK can lead to clinical response in T-cell malignancies is unknown. We hypothesized that ibrutinib-mediated ITK inhibition in T-cell lymphoma would result in decreased signaling through the T-cell receptor pathway and promote antitumor immune response by driving selective cytotoxic Th1 CD4 effector T-cell differentiation. This pilot clinical trial evaluated 2 dose levels of ibrutinib: 560 and 840 mg orally daily. Fourteen patients with relapsed, refractory peripheral T-cell lymphoma and cutaneous T-cell lymphoma were enrolled. Both dose levels were safe and well tolerated, and no dose-limiting toxicities were observed. One patient achieved a partial response (overall response rate, 8% [1/13]). ITK occupancy studies demonstrated a mean occupancy of 50% (range, 15%-80%). Higher ITK occupancy of more than 50% correlated with higher serum levels of tumor necrosis factor-α and interferon-γ and favored a Th1 phenotype. Our data suggest that ibrutinib inhibition of ITK has limited clinical activity in T-cell lymphoma. This study is registered at www.clinicaltrials.gov as #NCT02309580.
引用
- Kumar A, Vardhana S, Moskowitz AJ, et al. Pilot trial of ibrutinib in patients with relapsed or refractory T-cell lymphoma. Blood Adv. 2018. PMID: 29669753. doi:10.1182/bloodadvances.2017011916
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。